Liao Xue-Yan, Zhou Zhen-Zuo, Wei Fu-Bang, Qin Han-Ning, Ling Yuan, Li Rong-Cheng, Li Yan-Ping, Nong Yi, Sun Kui-Xia, Li Jie, Zhuang Hui
Department of Microbiology and Infectious Disease Center; School of Basic Medical Sciences; Peking University Health Science Center; Beijing, PR China.
Guangxi University of Science and Technology; Liuzhou, PR China.
Hum Vaccin Immunother. 2014;10(1):224-31. doi: 10.4161/hv.26311. Epub 2013 Sep 9.
The prevalence of hepatitis B surface antigen (HBsAg) in a population aged 15 y or older was high in China, but an immunization strategy for this population was unavailable. We investigated the seroprevalence of hepatitis B and immune response to HBV vaccine in Chinese college students (n=2040 participants), 11.1%, 80.8%, and 8.1% had confirmed, unknown and no HBV vaccination history, respectively. The seropositive rates for HBsAg, anti-HBs sole and anti-HBs plus anti-HBc were 12.6%, 25.7%, and 30.1%, respectively. The HBsAg seropositive rate was significantly lower in participants with confirmed HBV vaccination history than in those with unknown or no vaccination history (5.3%, 13.6%, and 12.6%, respectively, P=0.0019). The anti-HBs alone seropositive rate was significantly higher in participants with confirmed HBV vaccination history than in those with unknown or no vaccination history (37.6%, 25.3%, and 13.8%, respectively, P<0.0001). Participants negative for HBsAg, anti-HBs, and anti-HBc at baseline (n=600) were given three doses of recombinant HBV vaccine (GlaxoSmithKline) at month 0, 1, and 6. Robust immune response was elicited after two and three doses (seroprotective rate: 91.9% and 99.0%, respectively, and geometric mean concentration [GMC]: 95.8 and 742.6 IU/L, respectively). Fourteen months after the third dose, the anti-HBs seroprotective rate of the group remained more than 97%. The seroprotective rates and GMCs did not differ significantly by vaccination history. This study suggested that three doses of 20 μg HBV vaccine were needed for college students negative for HBsAg, anti-HBs, and anti-HBc to ensure high seroprotective rates and concentrations.
在中国，15岁及以上人群中乙肝表面抗原（HBsAg）的流行率很高，但该人群尚无免疫策略。我们调查了中国大学生（n = 2040名参与者）的乙肝血清流行率及对乙肝疫苗的免疫反应，其中分别有11.1%、80.8%和8.1%的人有确认的、未知的和无乙肝疫苗接种史。HBsAg、单纯抗-HBs及抗-HBs加抗-HBc的血清阳性率分别为12.6%、25.7%和30.1%。有确认乙肝疫苗接种史的参与者的HBsAg血清阳性率显著低于有未知或无疫苗接种史的参与者（分别为5.3%、13.6%和12.6%，P = 0.0019）。有确认乙肝疫苗接种史的参与者的单纯抗-HBs血清阳性率显著高于有未知或无疫苗接种史的参与者（分别为37.6%、25.3%和13.8%，P<0.0001）。基线时HBsAg、抗-HBs和抗-HBc均为阴性的参与者（n = 600）在第0、1和6个月接种了三剂重组乙肝疫苗（葛兰素史克公司生产）。接种两剂和三剂后均引发了强烈的免疫反应（血清保护率：分别为91.9%和99.0%，几何平均浓度[GMC]：分别为95.8和742.6 IU/L）。第三剂接种后14个月，该组的抗-HBs血清保护率仍超过97%。血清保护率和GMCs在不同疫苗接种史之间无显著差异。本研究表明，对于HBsAg、抗-HBs和抗-HBc均为阴性的大学生，需要接种三剂20μg乙肝疫苗以确保高血清保护率和浓度。
